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Abstract
Self-assembly of multidomain peptides (MDP) can be tailored to carry payloads that modulate the 
extracellular environment. Controlled release of growth factors, cytokines, and small-molecule 
drugs allows for unique control of in vitro and in vivo responses. In this study, we demonstrate 
this process of ionic cross-linking of peptides using multivalent drugs to create hydrogels for 
sustained long-term delivery of drugs. Using phosphate, heparin, clodronate, trypan, and suramin, 
we demonstrate the utility of this strategy. Although all multivalent anions result in good hydrogel 
formation, demonstrating the generality of this approach, suramin led to the formation of the best 
hydrogels per unit concentration and was studied in greater detail. Suramin ionically cross-linked 
MDP into a fibrous meshwork as determined by scanning and transmission electron microscopy. 
We measured material storage and loss modulus using rheometry and showed a distinct increase in 
G′ and G″ as a function of suramin concentration. Release of suramin from scaffolds was 
determined using UV spectroscopy and showed prolonged release over a 30 day period. Suramin 
bioavailability and function were demonstrated by attenuated M1 polarization of THP-1 cells 
compared to positive control. Overall, this design strategy has allowed for the development of a 
novel class of polymeric delivery vehicles with generally long-term release and, in the case of 
suramin, cross-linked hydrogels that can modulate cellular phenotype.
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INTRODUCTION
Multidomain peptide-based hydrogels present a novel platform for delivery of small-
molecule drugs, growth factors, and cells.1–5 Amphiphilic MDPs have demonstrated the 
ability to self-assemble as a function of amino acid composition and ionic buffers (e.g., 
Mg2+/Ca2+/PO43−).6,7 The specific MDP used in this study, 
KSLSLSLRGSLSLSLKGRGDS, which we call SLac, has been previously reported.2 SLac 
is composed of a central block of alternating hydrophilic serine and hydrophobic leucine 
residues, flanked on both sides with lysines that aid in its solubilization. Antiparallel β sheet 
formation creates a facial amphiphile with the side chains of leucine and serine constituting 
the hydrophobic and hydrophilic faces, respectively. Association of the antiparallel β sheets 
in a bilayer facilitates fiber formation so that the nonpolar leucine side chains are 
sequestered away and hydroxyl groups of serine remain exposed to the aqueous medium 
(Figure 1).
To augment the peptides’ function, an –LRG– moiety is present to facilitate biodegradation, 
and an –RGDS sequence to promote cell adhesion. At neutral pH, the protonated amines of 
the lysine residues resist molecular self-assembly of growing fibers. The resulting molecular 
frustration limits the extent of fibrillation. The addition of high-ionic-strength buffers or 
polyvalent anions can specifically aid in relieving molecular frustration, shielding positive 
or negative charges and allowing formation of long-range microscopic fibers.7,8 Noting the 
propensity for fiber growth with charge shielding because of polyvalent anions, we 
hypothesized that the addition of specific drug molecules with polyvalency to MDP 
hydrogels may aid in sequestration and controlled delivery. Here, we have investigated this 
notion with the use of several polyvalent drugs. These include heparin, clodronate, trypan, 
and suramin (Figure 2). All of these molecules resulted in the rapid formation of high-
quality hydrogels. Because suramin resulted in the strongest hydrogels per unit 
concentration used, we focused most of our characterization on suramin–SLac hydrogels.
The importance of controlling delivery of drugs is underscored by two key facets: (i) the 
desire to minimize systemic side effects of drugs such as chemotherapeutics while treating 
local regions of tissue in the immediate vicinity of pathologies with high doses of drug and 
(ii) tuning the delivery of drugs allows for sustained dosing without reducing the frequency 
and quantity of drug delivered. For example, treatment options for neoplastic disease 
typically involve radiation, chemotherapeutics, and noninvasive/minimally invasive 
treatments if diagnosed in early stages. For late-stage solid tumors, (e.g., glioblastoma 
multiforme) treatment involves surgical resection, coupled with postoperative radiation 
and/or chemotherapy.9–11 Systemic chemotherapeutics are typically used in high 
concentrations so that malignancies in the far reaches of the extracellular space still receive 
the minimum effective therapeutic dosage at the cost of systemic side effects.10–12 To 
counteract this, biocompatible polymers with anticancer payloads can be administered 
during surgical resection.13,14 This release strategy may potentially reduce the immune-
compromising chemotherapeutic burden, allow targeted chemotherapy, and reduce localized 
malignancy.15,16 Further, this strategy with controlled prolonged release can be extended to 
a variety of other multivalent drug candidates such as heparin (for prolonged anticlotting), 
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trypan (for localized treatment of parasites), and clodronate (for localized osteoporosis 
treatment).
RESULTS AND DISCUSSION
To determine material–drug interactions, we first noted the propensity for MDP to form 
robust hydrogels when like charges were shielded by negative ions, such as PO43−, allowing 
fiber cross-linking (Figure 1).
Extending from this, we noted the potential for a variety of anionic drugs to participate in a 
similar role, while potentially providing higher mechanical strength because of their 
conformation, molecular weight, and charge density (Figure 2). To determine which of these 
strategies would best cross-link MDP, we used parallel-plate rheometry.
Rheological characterization of hydrogel scaffolds when cross-linked with multivalent drugs 
may help elucidate potential mechanisms for cross-linking. Similar therapeutic doses of 
drugs were chosen for loading into hydrogels. Therapeutic doses approximate the 
concentration of low suramin, Figure 3. Low to high suramin loading spanned the range of 
concentrations that would diffuse to tissue or be bolus-dosed. All multivalent drugs showed 
a marked increase in G′ and G″ as a function of concentration (p < 0.01) (Figure 3). Given 
the high G′ and G″, the gels created were easily handleable and manipulable. Uniquely, 
depending on the cross-linking molecule, distinct rheological properties were noted. 
Increasing PO43− buffer ionic strength from 5 to 38.5 mM resulted in a significant increase 
in mechanical strength. Extending this notion of phosphate-based cross-linking, a clinically 
relevant diphosphonate used for bone healing, clodronate disodium, also resulted in a 
distinct increase in G′/G″ over that of phosphate alone or saline. The two phosphonate 
groups of clodronate are capable of shielding a greater number of charges and creating 
cross-links to multiple MDPs. To test this hypothesis, heparin, a large molecule with several 
negative charges, was chosen next. Heparin-loaded gels showed a significant increase in 
mechanical strength over that of PO43− but not that of clodronate alone. Further 
investigating functionality, a polysulfonate, trypan blue, typically used in cell culture 
viability assays, cross-linked MDP with a similar distinct increase in G′/G″. However, 
increases in mechanical responses yield gels of similar strength to those cross-linked with 
heparin. Finally, suramin, with six sulfonate groups, at a similar concentration, showed a 
much higher increase in strength (an order of magnitude higher G′/G″) as compared to other 
drugs used. Although the concentration and total number of charges in heparin gels is the 
greatest, gels prepared with suramin displayed the highest increase in strength (highest G′ 
and G″, Figure 3). This suggests that suramin has a conformationally and structurally 
suitable architecture in the presence of MDP to aid in its shielding of charges and cross-
linking. An illustrative movie shows how we hypothesize interactions between suramin and 
MDP (Movie 1).
Previous reports from our group have demonstrated the cross-linking potential for small 
multivalent molecules such as PO43− and drugs such as heparin.2,3,5 Basic modeling of the 
multivalent-drug–SLac interaction suggests that at neutral pH deprotonated charged groups 
can interact with several positively charged terminal lysine amine groups reducing charge–
Kumar et al. Page 3
J Am Chem Soc. Author manuscript; available in PMC 2015 October 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
charge repulsion and promoting intra- and interpeptide cross-linking. Extended to suramin, 
we hypothesize that negatively charged sulfonate residues cross-link positively charged 
lysine side chains (Figure 1). FTIR spectroscopy of hydrogels showed a characteristic 
extended β-sheet hydrogen-bonding peak between 1610–1630 cm−1 and a characteristic 
antiparallel β-sheet peak at 1695 cm−1 for all peptide mixtures (Figure 4A). Circular 
dichromism (CD) spectra similarly showed the presence of β-sheet secondary structure, with 
a minimum around 216 nm and maximum around 195 nm (Figure 4B). Formation of a 
fibrous structure within hydrogels at high concentrations of suramin/high ionic strength 
resulted in lower peak magnitudes at the 195 nm maxima. Peptide hydrogels that formed 
were optically clear and conformed to the shape of the mold they were cast in (Figure 4C). 
Microstructure of peptide scaffolds, probed using TEM and SEM, showed formation of a 
nanofibrous matrix (Figure 4D,E).
CONTROLLED RELEASE OF AN IONICALLY SEQUESTERED DRUG
Previous studies have shown the ability to tailor MDP with unique functionality on the basis 
of peptide sequence.2 Additionally, MDP can be loaded with drugs, growth factors, 
cytokines, and cellular secretome.1,2,17 As noted, chemical cross-linking of drugs with 
subsequent controlled release can strongly promote localized tissue responses and obviate 
systemic side effects. To this end, the potential of suramin as a potent antiangiogenic, 
antineoplastic, and antimicrobial drug to serve as a chemical cross-linker as demonstrated 
above was noted. Given suramin’s high IV dosing and frequency of dosing (1 g/3–7 days in 
adults), delivery of suramin in situ may prove to be advantageous. However, concerns exist 
over retention of suramin at the delivery site and leakage of the drug into lymphatic 
circulation. This may be reduced by ionically cross-linked suramin sequestered within 
hydrogels with slow, steady release (Figure 1, Figure 5). Suramin cross-linked gels showed 
long-term release at both low and high concentrations, with much of the drug still present in 
the carrier hydrogel at 30 days (Figure 5). At high suramin loading (1.0 mg of suramin, 2.0 
mg of peptide) hydrogel scaffolds showed an initially linear cumulative mass release 
followed by a tapering off to 57.9 ± 1.1% with the rest of the drug (42.1%) remaining 
trapped within the hydrogel. At the lower suramin loading (0.1 mg of suramin, 2.0 mg of 
peptide), hydrogel scaffolds exhibited significantly lower cumulative release, 38.7 ± 3.2%, 
with the rest of the drug (61.3%) remaining trapped within the hydrogel (Figure 5B,C). 
Modeling of suramin release from polymers was performed to help determine the 
mechanism of release, as detailed in the Experimental Methods.
Release from 10 mg/mL loaded gels was diffusion dependent, t ≈ 0.5, R2 = 0.972.18 Release 
from 1 mg/mL loaded gels was non-Fickian-diffusion-/case II-transport-dependent, t ≈ 1.0, 
R2 = 0.993, suggesting erosion of hydrogel ionic cross-links was releasing suramin.18 First 
derivatives of release profiles showed that release rates were initially faster for both loading 
concentrations, which then tapered after 2 weeks to a near-linear release rate (Figure 5D). 
The aggressive design of the release experiment, with release being probed daily, may 
overestimate release from hydrogel scaffolds because diffusive and convective transport 
enhances drug release, and the suramin reservoir concentration in the release media is 
depleted. However, we assayed release aliquots over a shorter time period more frequently 
(hr vs day) and determined no significant difference in kinetics of release (Figure 5A).19 
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Given the release data, we hypothesize that the immediate microenvironment will be 
affected by low concentrations of the drug over the first 30 days, with much of the suramin 
release being dictated by cellular adhesion to MDP hydrogels, mediated by an –RGDS 
terminal sequence, and degradation of MDP matrix, mediated by MMP-susceptible –LRG– 
domain. Sustained and targeted delivery of suramin has been a goal of several groups, 
liposomal encapsulation of suramin for antiviral applications,20 encapsulation of suramin/
paclitaxel into PLLA/PLGA microparticles for cancer treatment,21 and local delivery to 
inhibit neointimal hyperplasia postangioplasty,22 to name a few. However, of primary 
concern with any of these techniques is the release, detailed above, and bioavailability, 
detailed below, of the suramin after loading into the carrier.
PRESERVATION OF BIOLOGICAL ACTIVITY IN IONICALLY CROSS-LINKED 
GELS
Drug release from polymeric scaffolds for sustained release has been sought after for 
decades.10,12,15,23–26 Several strategies have been attempted for the capture of drugs 
including dissolving tablets, micelles for hydrophobic drugs, multiwalled microparticles, 
polymer wafers, covalent immobilization into carriers or onto surfaces, and ionic layer-by-
layer self-assembly, to name a few. Of concern is the unfavorable interaction of polymeric 
carriers with loaded drugs or surrounding tissue, such as covalent linker addition for 
conjugation to scaffolds or surfaces that may attenuate activity of functionality of drugs or 
non-natural degradation products that may elicit an inflammatory response, complicating 
drug action or the nonconforming nature of solid delivery systems.9,10,12,15,16,25,26 In this 
article, we have explored the potential for a drug to actively interact with its carrier by cross-
linking it. Similar studies by our group and others have shown limited inflammatory 
responses with synergistic activity of passively loaded cytokines or growth factors.1,3,4,17 As 
a vital next step, it was important to confirm the maintenance of activity of ionically 
sequestered drugs after loading into MDP carriers. Because suramin is known to have 
distinct effects on growth factors/growth factor receptors, we utilized suramin-releasing gels 
to determine biological activity.27 Suramin-loaded SLac hydrogels were seeded with THP-1 
macrophages. THP-1 cells were chosen because of their neoplasticity, monocytic origin, and 
establishment as an human cell line.28 Lipopolysaccharide (LPS)-activated THP-1 
macrophages adhered to drug-laden SLac hydrogels. These cells were exposed to ionically 
trapped suramin, which decreased M1 polarization with decreased levels of TNF-α and 
IL-1β compared to M1 cells (Figure 6). This is probably due to known P2Y receptor 
antagonism, as reported previously.29 Together, this data demonstrates preservation of 
suramin effector functionality and inhibition of proinflammatory M1 phenotype 
development in LPS-induced human monocytic leukemia cell line THP-1 cells.
MEASURING IN VIVO ACTIVITY
Suramin-cross-linked SLac hydrogels may have potential for localized drug delivery. To 
demonstrate this, high-concentration suramin was used to cross-link 1 wt % SLac hydrogels. 
Suramin-cross-linked gels, compared to PO43−-cross-linked ones, showed significantly 
higher stiffness (G′/G″, Figure 3). However, hydrogels were still injectable, allowing site-
delivered subcutaneous implantation. Suramin hydrogels showed a marked decrease in 
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cellular infiltration compared to PO43−-cross-linked SLac hydrogels (Figure 7). This 
potentially may be due to the increased stiffness of matrices that encumber cellular 
infiltration.30–32 Furthermore, a significant increase in immunostained M2 macrophages was 
observed in suramin gels compared to unloaded gels. MDP hydrogels have previously 
demonstrated the lack of a fibrous capsule and excellent ECM integration.5,33 Suramin-
loaded hydrogels show a similar lack of fibrous encapsulation and excellent integration 
(Figure 7). These results demonstrate the minimal effect implanted gels have on surrounding 
tissue. Specifically, (i) cellular infiltrate was localized to the implant, (ii) M2 macrophage 
polarization was localized to within the implant and the immediate vicinity, and (iii) no 
fibrous tissue walling-off of the implant was observed. Having established these key 
chemical and biomechanical facets, future studies in sophisticated in vivo cancer models can 
now be envisioned. These syringe-deliverable constructs may help a variety of strategies that 
allow localized drug delivery,34 complemented by functional peptide signaling,33 that 
ultimately offer another tool for targeted therapeutics.
In this study, we have demonstrated the ability of polyvalent drugs to ionically cross-link 
multidomain peptides. Specifically, we modeled interactions of peptides with drugs, 
showing stabilization of an antiparallel β-sheet structure that enhanced long-range 
nanofibrous meshwork formation and mechanically robust gels. We further demonstrated 
cross-linking of scaffolds using a variety of clinically relevant polyvalent drugs such as 
suramin, clodronate, heparin, and trypan blue. Sequestered suramin was shown to slowly 
release from hydrogel scaffolds, with less than 40–60% releasing over the first 30 days, 
depending on loading concentration. Preservation of suramin activity on attenuation of M1 
phenotype of LPS-stimulated THP-1 monocytic leukemia cells was demonstrated. 
Subsequent in vivo studies in mammalian subcutaneous tumor-resection models will aim to 
demonstrate attenuated scaffold infiltration, muted angiogenesis, and limited malignancy as 
a function of suramin loading.
EXPERIMENTAL METHODS
All chemicals and reagents were purchased from Sigma-Aldrich, unless otherwise noted.
Peptide Design and Characterization
Multidomain peptides were designed on the basis of previously published sequences from 
our laboratory: SLac, K-(SL)3-(RG)-(SL)3-K-GRGDS.2 All peptides, resin, and coupling 
reagents were purchased from Aapptec (Louisville, KY). Standard solid-phase peptide 
synthesis was performed on an Apex Focus XC (Aapptec) apparatus using Rink amide resin 
with 0.37 mM loading and N-terminal acetylation. After cleavage from resin, crude mass 
was checked prior to dialysis with 500–1200 MWCO dialysis tubing (Sigma-Aldrich, St. 
Louis, MO) against Milli-Q water. Peptides were subsequently lyophilized, confirmed for 
purity using time-of-flight electrospray ionization mass spectrometry, MicroTOF ESI 
(Bruker Instruments, Billerica, MA), and reconstituted at 20 mg/mL in sterile 298 mM 
sucrose.
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Peptide (Nanofiber)–Drug Interaction
Peptides were modeled in PyMOL Molecular Graphics System, version 1.5.0.5 
(Schrödinger, LLC, San Diego, CA) on the basis of previous published work. Previously 
published work from our lab indicates that the peptide chains form an antiparallel β sheet 
that sequesters the nonpolar residues away from water. Hydrogen bonding between the 
sandwiched β sheets facilitates 1D propagation in nanofibers. The antiparallel β-sheet 
arrangement of peptides in SLac was confirmed using Fouriertansform infrared 
spectroscopy (FTIR). For modeling in PyMOL, 8–10 peptide chains were arranged 
adjacently in an antiparallel fashion with hydrophobic/hydrophilic faces (dependent on 
amino acid R chain) facing the same direction. The two hydrophobic faces were brought in 
proximity of each other as suggested by previous studies.8 Ioinc interactions between facial 
amphiphilic fibers were then hypothesized with suramin (RCSB DrugBank ID: DB04786).
Scanning Electron Microscopy and Transmission Electron Microscopy
Microscopic morphology of SLac scaffolds gelled with suramin was determined using 
scanning electron microscopy (SEM) and transmission electron microscopy (TEM). For 
SEM, samples were ethanol-dehydrated, critical-point-dried, sputter-coated with 7 nm gold 
(Denton, Moorestown, NJ), and imaged using an FEI Quanta 400 ESEM (FEI Company, 
Hillsboro, OR). Fibrillar network for SLac was confirmed using TEM. For TEM, samples 
were prepared by adding peptide solution directly onto Quantifoil R1.2/1.3 holey carbon 
mesh on copper grids. Excess peptide was blotted, and the grid was dried prior to negative 
staining using 2.0% pH 7 phototungstic acid for 8 min. Dried grids were imaged using a 
JEOL 2010 microscope (120 kV).
Circular Dichroism
All CD experiments were performed on a Jasco J-815 spectropolarimeter equipped with a 
Peltier temperature-controlled stage. All spectra were collected from 190 to 250 nm at 25 
°C. Peptide was dissolved in sucrose at 2 wt %. CD samples were prepared at pH 7.4 by 
gelling peptide in equal volumes of 0.9% saline, Hank’s balanced salt solution (HBSS), 7.7 
mM PO43−, and 1.0 or 0.1 mg/mL suramin. For each experiment, 20 μL aliquots of each 
sample were gelled in situ on a quartz cell with a path length of 0.01 cm. The molar residual 
elipticity (MRE) was calculated from the following formula:
where θ is the observed ellipticity in millidegrees, m is the molecular weight in grams per 
mole (g mol−1), C is the concentration in milligrams per millileter (mg ml−1), l is the path 
length of the cuvette in centimeters (cm), and nr is the number of amino acids in the peptide.
Attenuated Total Reflectance Infrared Spectroscopy
Aliquots (10 μL each) of peptide gel at pH 7.4 were pipetted onto a Golden Gate diamond 
window and dried under nitrogen until a thin film of peptide was achieved. IR spectra (64 
accumulations) were taken using a Jasco FT/IR-660 spectrometer.
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Mechanical Analysis
Peptide solutions were made by dissolving lyophilized SLac in 298 mM sucrose/water at a 
concentration of 2 wt %, pH 7.4. Hydrogels were constructed by addition of HBSS at a 1:1 
ratio. Multivalent drugs were added at similar concentrations, approximating physiological 
doses, to SLac solutions with final concentrations of 0.4 mM SLac (1 wt %); concentration 
of positive lysine charges, 0.8 mM; 3.8 mM (0.5 wt %) or 0.38 mM (0.05 wt %) suramin; 
3.2 mM trypan blue (0.2 wt %); ~2.78 mM heparin (5 wt %); 3.4 mM clodronate disodium; 
38 and 5 mM phosphate buffer; and 0.9% saline. Negatively charged polyvalent ions in 
buffer solution facilitated intermolecular ionic interactions with lysine residues, cross-
linking the hydrogel. Rheological behavior of peptide hydrogels was determined using an 8 
mm parallel-plate geometry at a gap of 250 μm. A 50 μL sample of hydrogel was 
constructed and, within 30 min, placed on stainless-steel plates of a rheometer (AR-G2, TA 
Instruments). A frequency sweep (0.1–100 Hz, at constant 1% strain), strain sweep (0–
1000% strain, at 1 Hz), and shear recovery (1% strain for 30 min, 100% strain for 60 s, 1% 
strain for 30 min) were performed. We ensured the phase angle δ ≤ 90° to ensure no 
slipping.
Suramin Drug Loading and Release
Suramin was dissolved in 0.9% saline and loaded into MDP hydrogel (100 μL of SLac 
dissolved in 298 mM surcose + 100 μL of drug/saline) in microcentrifuge tubes. Release 
media (1 mL of HBSS) was added to gels placed in a humidified, 5% CO2 cell culture 
incubator at 37 °C. Aliquots (200 μL each) of release media were assayed daily with 
replenishment for 30 days. To determine short-term release kinetics, in a separate setup, 
aliquots were assayed at 1, 2, 4, 8, 12, 24, 48, and 72 h. Concentration of drug was 
determined using UV spectrophotometry at 313 nm, n = 5. Mass-release data were plotted as 
a function of cumulative release of drug in Sigmaplot (Systat, Chicago, IL). Drug release 
was modeled using the Korsmeyer–Peppas equation.35
Monocyte/Macrophage Culture and Differentiation
Human monocytic leukemia cell line THP-1 cells (ATCC, Manassas, VA), were cultured in 
media (ATCC-formulated RPMI-1640 medium supplemented with 0.05 mM 2-
mercaptoethanol, fetal bovine serum (10%), 100 mg/mL penicillin, and 100 mg/mL 
streptomycin) at a concentration of 200 000 cells/mL. Cells were grown in suspension and 
diluted when concentration reached 0.8–1.0 million cells/mL. Media was changed every 3 
days as necessary. THP-1 monocytes were cultured to M0 macrophages by pulsing with 5 
nm phorbol 12-myristate 13-acetate, phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) 
for 5 min. Adherent M0-differentiated cells were incubated with interferon gamma (IFN-γ, 
20 ng/mL, Gibco, Life Technologies, Carlsbad, CA) and LPS (20 ng/mL, Sigma-Aldrich) 
for M1 (R&D Systems) for 24 h at 37 °C. For macrophage plasticity studies, THP-1 cells 
were differentiated to M0 macrophages as described. An aliquot of cells (0.5 M cells/cm2) 
were seeded atop 100 μL of SLac hydrogels made with 1 wt % suramin (final = 1 wt % 
peptide, 0.5 wt % suramin), 0.1 wt % suramin (final = 1 wt % peptide, 0.05 wt % suramin), 
or PBS (final = 1 wt % peptide), n = 5, in 16-well glass-bottomed glass slides. Media 
containing IFN-γ (20 ng/mL, Gibco, Life Technologies, Carlsbad, CA) and LPS (20 ng/mL, 
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Sigma-Aldrich) was added atop hydrogels to stimulate M1 phenotype. Control hydrogels 
were gelled using PBS. M0 control did not receive IFN-γ/LPS; positive control media was 
supplemented with 0.5 or 0.05 mg of suramin (identical to mass of suramin in gels).29 After 
24 h, media aliquots were stored at −80 °C, and proinflammatory markers IL-1β and TNF-α 
were measured (Biolegend, San Diego, CA). Gels were then fixed in formalin and 
immunostained for M1 marker CCR7 (Novus, Littleton, CO) and DAPI. The number of 
CCR7+ cells divided by the number of nuclei gave the M1 polarization ratio, quantified by 
counting six random image sections at 20× magnification per sample, of five samples per 
group, using NIH ImageJ.
Subcutaneous Implants
All experiments were approved by the Rice University Institutional Animal Care and Use 
committee. Female Wisar rats (225–250g, Charles River Laboratories, Wilmington, MA) 
were anesthetized using isofluorane (2% for induction and 1% for maintenance), dorsal 
aspect shaved, and sterilely prepped. Scaffolds were loaded in syringes, and 200 μL 
subcutaneous injections of each SLac and SLac+suramin (100 mg/mL) were made in four 
different 1.5-inch-spaced randomized sites on the dorsal aspect, on either side, between the 
lower thoracic and upper lumber vertebrae, n = 4 for each scaffold for 1 week. Rats were 
then euthanized using an overdose of isoflurane, CO2 asphyxiation, and bilateral thoracic 
puncture. The dorsal skin was removed around the entire implant, washed with PBS, and 
fixed in neutral buffered formalin for 24 h prior to processing. Tissue was then processed 
into paraffin blocks, sectioned at 7 μm, deparraffinized, and stained for cellular infiltrate 
using hematoxylin and eosin (H&E), and nuclei were counted in three random fields per 
sample and averaged over all samples from each group using ImageJ (NIH, Bethesda, MD). 
Infiltration of implants was graded on a 5 point scale: 1 = periphery (<50%, with large parts 
of scaffold uninfiltrated, center uninfiltrated), 2 = 50–80% (with small regions of scaffold 
exposed, center uninfiltrated), 3 = center infiltrated (with small regions of scaffold exposed), 
4 = few to no scaffold regions visible, and 5 = implant indistinguishable from native tissue 
except for complete dense cellular repopulation. Cellular infiltrate was phenotyped using 
immunostaining. Immune cell staining was performed for panmacrophage, rabbit antirat 
CD68 (Abcam); M1 macrophages, goat antirat CCR7 (Novus); and M2 macrophages, mouse 
antirat CD163 (AbDSerotec). Secondary antibodies used were (i) AF647 donkey antirabbit, 
(ii) AF488 donkey antigoat, and (iii) AF555-donkey antimouse (Life Technologies). Nuclei 
were counterstained with DAPI (Life Technologies). Cellular infiltrate was quantified using 
NIH ImageJ, and the M1/M2 polarization ratio was determined.
Ionic cross-linking of scaffolds by drugs is a novel approach to the preparation of drug-
delivering hydrogels. We have previously shown that heparin, a highly charged 
proteoglycan, can attenuate drug release from MDP.3,4,17,34 In this study, we show that 
heparin and a number of other small-molecule drugs act as the hydrogel cross-linking agent 
and are therefore effectively incorporated into the MDP. These ionically cross-linked MDPs 
show improved rheological performance because of the charged interaction of drugs and 
scaffolds (Figure 3). The resulting hydrogel is composed of nanofibrous β sheets and is 
cross-linked in a fashion similar to our previous PO43−-mediated charge-shielding approach 
to self-assembly (Figure 1 and Movie 1). Covalent attachment of drugs directly to the 
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scaffold can be an effective method to present drugs and attenuate their release.36 
Conventional covalent immobilization and physisorption strategies can result in altered 
chemical presentation, introduction of non-native polymeric sequences, or systemic side 
effects.9,10,16,35 Here, we show attenuation of suramin release over a long period, localized 
delivery via syringe, and maintenance of biological activity. Importantly, because the drug 
in this case is not simply cargo within the hydrogel but intimately participating in its 
structure, the release duration is very long (Figure 5). Most hydrogels loaded with small-
molecule drugs, and even those loaded with relatively large proteins, result in short-term 
burst release that has limited their applicability.9,10,16,35 MDP interior hydrophobic domains 
may provide next generation strategies for solubilization of hydrophobic drugs while 
allowing aqueous solubility of nanofiber conjugates.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic of molecular self-assembly. Designer peptides with –RGDS terminal sequence. 
Main SL-repeat regions arrange antiparallel to each other and hydrogen bond into sheets. 
Polyvalent suramin allows for intra- and intermolecular hydrogen bonding and ionic 
interaction with terminal lysines. Stabilized short fibers’ terminal charges are screened, 
allowing fiber growth and polymerization into hydrogel networks.
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Figure 2. 
Polyanionic drugs used. A variety of polyanionic drugs that are clinically important were 
chosen for ionic cross-linking with matrices.
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Figure 3. 
Rheological properties of cross-linked peptide hydrogels. Higher concentrations of negative 
ion charge shield MDP charges to a greater extent, yielding increased storage moduli (G′) 
and loss moduli (G″). Significant increases were noted when PO43− concentration was 
increased, compared to prior values (*, 5 mM PO43− from Galler et al., G′ (dashed line), G″ 
(dotted line)).2 Increasing the density of PO43− groups, using bisphosphonate clodronate 
(Clod.), resulted in an increase in mechanical strength. Charge density did not result in 
significantly increased moduli when comparing heparin (Hep.) and trypan blue (Tryp.) at 
similar concentrations. Charge density and conformation of suramin resulted in an order of 
magnitude increase in mechanical strength with increase in concentration. Similar Greek 
letter indicates no statistically significant difference for each receptor (*, p < 0.01).
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Figure 4. 
Characterization of peptide structure. (A) FTIR spectroscopy showing characteristic peaks 
for the formation of a β-sheet structure when peptide is mixed with saline, HBSS, high-
ionic-strength phosphate, and two different suramin concentrations. (B) CD spectroscopy 
confirmed formation of β-sheet structure. Note that gels formed aggregates, resulting in 
lower minima/maxima intensity for higher concentration of suramin. For FTIR and CD, all 
samples were identically diluted as detailed in the Experimental Methods. (C) Peptide–drug 
mixtures cast in cylindrical molds create optically transparent gels that maintain their 
structure. (D) Peptide hydrogels with drug loading create nanofiber matrix seen in negative-
stain TEM, scale bar = 50 nm. (E) SEM of dehydrated hydrogel, scale bar = 1 μm.
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Figure 5. 
Drug release from scaffolds. (A) Short- and long-term drug release data overlapped. (B) 
Maximum cumulative suramin concentrations reach 0.6 mg/mL (for high loading) and 0.04 
mg/mL (for low loading). (C) Cumulative percentage mass released from scaffolds was 
determined, modeled, and (D) first derivative release rates determined.
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Figure 6. 
Macrophage polarization as a function of suramin loading. Suramin loading hydrogels 
repressed the expression of M1 macrophage marker CC chemokine receptor 7 (CCR7)+ and 
release of proinflammatory cyotkines (B) tumor necrosis factor alpha (TNF-α) and (C) 
interleukin 1 β (IL-1β).
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Figure 7. 
In vivo evaluation of scaffolds. (A) Scaffolds with suramin-loading show large platelets of 
MDP uninfiltrated (*), compared to (B) a similar region (*) in SLac-only scaffolds. (C) 
Quantification of infiltration showed a significantly lower number of cells, (D) infiltrating 
loaded scaffolds to a diminished extent, (E) with a greater M2 macrophage polarization. 
Representative images of suramin-loaded (F) and -unloaded (G) scaffolds shown. Nuclei, 
DAPI blue; macrophages, CD68-red; M1, CCR7-green; M2, CD163-purple. (*, p < 0.01).
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